GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosergen AB (FRA:8N1) » Definitions » Equity-to-Asset

Biosergen AB (FRA:8N1) Equity-to-Asset : 0.80 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biosergen AB Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Biosergen AB's Total Stockholders Equity for the quarter that ended in Sep. 2024 was €1.03 Mil. Biosergen AB's Total Assets for the quarter that ended in Sep. 2024 was €1.28 Mil.

The historical rank and industry rank for Biosergen AB's Equity-to-Asset or its related term are showing as below:

FRA:8N1' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.28   Med: 0.68   Max: 0.84
Current: 0.8

During the past 4 years, the highest Equity to Asset Ratio of Biosergen AB was 0.84. The lowest was -2.28. And the median was 0.68.

FRA:8N1's Equity-to-Asset is ranked better than
66.47% of 1512 companies
in the Biotechnology industry
Industry Median: 0.67 vs FRA:8N1: 0.80

Biosergen AB Equity-to-Asset Historical Data

The historical data trend for Biosergen AB's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosergen AB Equity-to-Asset Chart

Biosergen AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
-2.28 0.69 0.67 0.29

Biosergen AB Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.29 0.84 0.81 0.80

Competitive Comparison of Biosergen AB's Equity-to-Asset

For the Biotechnology subindustry, Biosergen AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosergen AB's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biosergen AB's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Biosergen AB's Equity-to-Asset falls into.



Biosergen AB Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Biosergen AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=0.189/0.644
=

Biosergen AB's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )=Total Stockholders Equity/Total Assets
=1.031/1.282
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biosergen AB  (FRA:8N1) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Biosergen AB Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Biosergen AB's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosergen AB Business Description

Traded in Other Exchanges
Address
Fogdevreten 2, Solna, SWE, 17165
Biosergen AB is a biotech company developing innovative antifungal drugs based on latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway, and several other places worldwide. The company is developing BSG005, a potentially disruptive antifungal drug, which has demonstrated significant safety and potency advantages over competing antifungals.

Biosergen AB Headlines

No Headlines